Balance Sheet
Liabilities and Shareholders Equity
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Non-Current Deffered Revenue (2018 - 2020)

KalVista Pharmaceuticals' Non-Current Deffered Revenue history spans 5 years, with the latest figure at $2.5 million for Q1 2020.

  • For Q1 2020, Non-Current Deffered Revenue fell 31.81% year-over-year to $2.5 million; the TTM value through Jan 2020 reached $2.5 million, down 31.81%, while the annual FY2019 figure was $3.3 million, 69.23% down from the prior year.
  • Non-Current Deffered Revenue for Q1 2020 was $2.5 million at KalVista Pharmaceuticals, down from $2.8 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $13.9 million in Q1 2018 and bottomed at $2.5 million in Q1 2020.
  • The 3-year median for Non-Current Deffered Revenue is $3.7 million (2019), against an average of $5.9 million.
  • The largest annual shift saw Non-Current Deffered Revenue plummeted 73.61% in 2019 before it tumbled 31.81% in 2020.
  • A 3-year view of Non-Current Deffered Revenue shows it stood at $4.7 million in 2018, then tumbled by 41.03% to $2.8 million in 2019, then fell by 9.22% to $2.5 million in 2020.
  • Per Business Quant, the three most recent readings for KALV's Non-Current Deffered Revenue are $2.5 million (Q1 2020), $2.8 million (Q4 2019), and $2.9 million (Q3 2019).